

# ESMO PRECEPTORSHIP PROGRAMME BREAST CANCER

Multidisciplinary management, standards of care,  
therapeutic targets and future perspectives

**Munich, Germany**  
**10-11 July 2026**

---

**CO-CHAIRS** Nadia Harbeck, Germany  
Peter Schmid, United Kingdom

**SPEAKERS** Frederique Penault-Llorca, France  
Alessandra Gennari, Italy  
John Conibear, United Kingdom  
Sherko Kümmel, Germany  
Daniela Paepke, Switzerland  
Shani Paluch-Shimon, Israel  
Rachel Wuerstlein, Germany

---

## LEARNING OBJECTIVES

- To enable the interdisciplinary discussion and collaboration in the care of patients with breast cancer
- To understand subtype-specific breast cancer management
- To improve the understanding of current pathological diagnostics
- To understand the current developments in loco-regional treatments
- To learn about the latest developments in neoadjuvant and adjuvant therapies
- To gain insight into the role of complementary and lifestyle interventions and supportive care
- To review approaches to the care of patients with advanced breast cancer
- To learn about specific needs of young patients with breast cancer

---

## ACCREDITATION

The programme of this event has been accredited with **11 ESMO-MORA category 1 points**.  
Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to [esmo.org](http://esmo.org).

---

## ORGANISATION AND CONTACTS

ESMO Head Office  
Education Department  
Via Ginevra 4, 6900 Lugano, Switzerland  
Email: [courses@esmo.org](mailto:courses@esmo.org)  
[www.esmo.org](http://www.esmo.org)



## Friday, 10 July 2026

09:00-09:05 5'	Opening remarks	Nadia Harbeck, DE Peter Schmid, UK
09:05-10:45 100'	<b>SESSION 1</b> Breast pathology and loco-regional treatment in EBC	<b>Chair:</b> Nadia Harbeck, DE
20'	Update on breast pathology: What do we need to know in the clinic? (e.g. liquid biopsy, molecular tumour board...)	Frederique Penault-Llorca, FR
10'	Q&A	All
30'	Contemporary breast and axillary surgery	Sherko Kümmel, DE
10'	Q&A	All
20'	Contemporary indications for radiation therapy	John Conibear, UK
10'	Q&A	All
10:45-11:15	Coffee break	
11:15-12:50 95'	<b>SESSION 2</b> Systemic therapy in EBC	<b>Chair:</b> Peter Schmid, UK
25'	Luminal	Nadia Harbeck, DE
10'	Q&A	All
20'	Triple negative	Peter Schmid, UK
10'	Q&A	All
20'	HER2 positive	Rachel Wuerstlein, DE
10'	Q&A	All
12:50-13:50	Lunch	
13:50-15:30 100'	<b>SESSION 3</b> Special situations	<b>Chair:</b> Nadia Harbeck, DE
20'	Young women: Genetics, counselling and therapeutic consequences	Shani Paluch-Shimon, IL
10'	Q&A	All
30'	Lifestyle, complementary and alternative medicine	Daniela Paepke, CH
10'	Q&A	All
20'	Young women: Special issues (pregnancy, fertility, etc.)	Shani Paluch-Shimon, IL
10'	Q&A	All
15:30-16:00	Coffee break	
16:00-17:30 90'	<b>SESSION 4</b> Participants clinical case discussion - EBC	<b>Chairs:</b> Peter Schmid, UK Nadia Harbeck, DE
90'	Participants clinical case discussion (6x15')	Faculty
20:00	Dinner	

## Saturday, 11 July 2026

<b>09:00-10:30</b> 90'	<b>SESSION 5</b> Participants clinical case discussion - MBC	<b>Chairs:</b> Peter Schmid, UK Nadia Harbeck, DE
90'	Participants clinical case discussion (6x15')	Faculty
<b>10:30-11:00</b>	<b>Coffee break</b>	
<b>11:00-11:30</b> 30'	<b>SESSION 6</b> Loco-regional treatment in MBC	<b>Chair:</b> Nadia Harbeck, DE
20'	Loco-regional therapy in advanced breast cancer: Radiotherapy (oligoprogression in brain mets)	John Conibear, UK
10'	Q&A	All
<b>11:30-13:30</b> 120'	<b>SESSION 7</b> Systemic therapy in MBC	<b>Chair:</b> Peter Schmid, UK
20'	Advanced triple negative breast cancer	Alessandra Gennari, IT
10'	Q&A	All
20'	Advanced HER2 positive breast cancer	Rachel Wuerstlein, DE
10'	Q&A	All
20'	Advanced luminal breast cancer (incl. HER2-low)	Alessandra Gennari, IT
10'	Q&A	All
20'	Management of side effects of immunotherapy and ADCs	Rachel Wuerstlein, DE
10'	Q&A	All
<b>13:30-13:35</b> 5'	<b>Closing remarks</b>	<b>Peter Schmid, UK</b> <b>Nadia Harbeck, DE</b>
<b>13:35-14:35</b>	<b>Lunch</b>	

Note: Each 15-minute slot for clinical case discussion includes a 7' case presentation and an 8' Q&A / panel discussion